AU2014215920B2 - Solid dispersion comprising amorphous cilostazol - Google Patents

Solid dispersion comprising amorphous cilostazol Download PDF

Info

Publication number
AU2014215920B2
AU2014215920B2 AU2014215920A AU2014215920A AU2014215920B2 AU 2014215920 B2 AU2014215920 B2 AU 2014215920B2 AU 2014215920 A AU2014215920 A AU 2014215920A AU 2014215920 A AU2014215920 A AU 2014215920A AU 2014215920 B2 AU2014215920 B2 AU 2014215920B2
Authority
AU
Australia
Prior art keywords
solid dispersion
cilostazol
methacrylic acid
acid copolymer
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014215920A
Other languages
English (en)
Other versions
AU2014215920A1 (en
Inventor
Naoki Kamada
Junichi Kawasaki
Atsuya NAKAMURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2014215920A1 publication Critical patent/AU2014215920A1/en
Application granted granted Critical
Publication of AU2014215920B2 publication Critical patent/AU2014215920B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
AU2014215920A 2013-02-06 2014-02-05 Solid dispersion comprising amorphous cilostazol Ceased AU2014215920B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-021475 2013-02-06
JP2013021475 2013-02-06
PCT/JP2014/053232 WO2014123244A1 (en) 2013-02-06 2014-02-05 Solid dispersion comprising amorphous cilostazol

Publications (2)

Publication Number Publication Date
AU2014215920A1 AU2014215920A1 (en) 2015-08-20
AU2014215920B2 true AU2014215920B2 (en) 2018-03-15

Family

ID=50184966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014215920A Ceased AU2014215920B2 (en) 2013-02-06 2014-02-05 Solid dispersion comprising amorphous cilostazol

Country Status (11)

Country Link
US (1) US9555026B2 (enExample)
EP (1) EP2953615B1 (enExample)
JP (2) JP5980449B2 (enExample)
KR (1) KR102205192B1 (enExample)
CN (1) CN105050586B (enExample)
AR (1) AR095143A1 (enExample)
AU (1) AU2014215920B2 (enExample)
CA (1) CA2899389C (enExample)
PH (1) PH12015501722A1 (enExample)
TW (1) TWI615157B (enExample)
WO (1) WO2014123244A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381945A (zh) * 2017-02-10 2019-10-25 阿尔图姆制药股份有限公司 口服给予的镓（iii）配合物的组合物
KR102114550B1 (ko) * 2018-07-10 2020-05-22 삼육대학교산학협력단 생리학적 체내 동태 연구 모델링을 이용한 약제학적 조성물의 제조 방법
CA3136081A1 (en) * 2019-05-03 2020-11-12 Azora Therapeutics, Inc. Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021448A1 (en) * 1995-01-10 1996-07-18 Otsuka Pharmaceutical Co., Ltd. Resin particle, medical material and pharmaceutical preparation containing said resin particle
WO2009051022A2 (en) * 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
WO2009139504A2 (en) * 2008-05-15 2009-11-19 Otsuka Pharmaceutical Co., Ltd. A solid pharmaceutical formulation
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683673A5 (de) * 1991-10-01 1994-04-29 Otsuka Pharma Co Ltd Antithromboseharz, Antithromboseröhrchen, Antithrombosefilm und Antithromboseüberzug.
JP3799093B2 (ja) * 1995-01-10 2006-07-19 大塚製薬株式会社 樹脂粒状物およびこれを含有する医療製剤
PT784974E (pt) * 1995-07-26 2003-09-30 Kyowa Hakko Kogyo Kk Preparacao de derivados de xantina numa dispersao solida
JPH11246404A (ja) 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
JP4748839B2 (ja) 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
CA2508840A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
CN1241566C (zh) * 2004-03-15 2006-02-15 深圳海王药业有限公司 西洛他唑固体分散体及其片剂制备方法
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
EP1970040A4 (en) 2005-12-22 2013-05-29 Otsuka Pharma Co Ltd METHOD FOR PRODUCING MEDICINAL WAX MATRIX PARTICLES, IN THE METHOD OF USING EXTRUDERS AND CILOSTAZOL-CONTAINING PREPARATION WITH DELAYED RELEASE
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
KR20080076440A (ko) * 2007-02-16 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2008138755A2 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
TW201010743A (en) * 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
WO2011027656A1 (en) 2009-09-04 2011-03-10 Semiconductor Energy Laboratory Co., Ltd. Transistor and display device
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021448A1 (en) * 1995-01-10 1996-07-18 Otsuka Pharmaceutical Co., Ltd. Resin particle, medical material and pharmaceutical preparation containing said resin particle
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
WO2009051022A2 (en) * 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
WO2009139504A2 (en) * 2008-05-15 2009-11-19 Otsuka Pharmaceutical Co., Ltd. A solid pharmaceutical formulation

Also Published As

Publication number Publication date
TWI615157B (zh) 2018-02-21
EP2953615B1 (en) 2018-05-23
CN105050586A (zh) 2015-11-11
CN105050586B (zh) 2017-12-08
HK1218618A1 (en) 2017-03-03
TW201440814A (zh) 2014-11-01
EP2953615A1 (en) 2015-12-16
JP2016193915A (ja) 2016-11-17
WO2014123244A1 (en) 2014-08-14
AU2014215920A1 (en) 2015-08-20
PH12015501722B1 (en) 2015-11-09
JP5980449B2 (ja) 2016-08-31
CA2899389C (en) 2021-02-16
AR095143A1 (es) 2015-09-30
JP2016506948A (ja) 2016-03-07
CA2899389A1 (en) 2014-08-14
US20150366859A1 (en) 2015-12-24
KR102205192B1 (ko) 2021-01-20
KR20150115859A (ko) 2015-10-14
PH12015501722A1 (en) 2015-11-09
US9555026B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
ES2993251T3 (en) Pharmaceutical compositions of nilotinib
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
CN107847490A (zh) 改进的地拉罗司制剂及制备其的方法
TW200848056A (en) Solid dispersion of a neurokinin antagonist
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
US20220362235A1 (en) Pharmaceutical compositions of cabozantinib
US20220280500A1 (en) Pharmaceutical compositions of cabozantinib
US20250248987A1 (en) Pharmaceutical compositions of cabozantinib
AU2014215920B2 (en) Solid dispersion comprising amorphous cilostazol
US20240415809A1 (en) Pharmaceutical combinations
JPWO2015199115A1 (ja) 経口投与用医薬組成物
HK1218618B (en) Solid dispersion comprising amorphous cilostazol
KR20190007370A (ko) 바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 우수한 안정성 및 용출률을 갖는 복합제제
GB2638418A (en) An orodispersible tablet of spironolactone and its process of preparation
KR20250041176A (ko) 나포라페닙을 포함하는 무정형 고체 분산물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired